A distinctive cardiac necrosis biomarker for early triaging chest pain patients. It rises faster to detectable levels compared to troponin in the event of an Acute Myocardial Infarction. This makes it suitable for PoC platforms.

Using cMyC reduces patients in observation groups in the Emergency Department => Cost saving for hospitals!

Recent publications have also shown its value in Acute Heart Failure.